spec sheet7 rows
Alestramustine An investigational antineoplastic (chemotherapy) agent that was never marketed. It is the L-alanine ester of estramustine, combining a nitrogen mustard alkylating fragment (normustine) with the estrogen estradiol via a carbamate linkage.
- Designed as a dual-mechanism prodrug combining a cytotoxic alkylating fragment with estrogen-driven tumor targeting
- Chemically related to estramustine, an agent historically used against hormone-responsive prostate cancer
- Related estrogen-linked chemotherapy agents carry risks of fluid retention and blood clotting
Overview
A chemo prodrug design that never made it out of the lab; it's a stepping stone to estramustine, not a standalone drug you'll find anywhere.
Mechanism
Alestramustine acts as a , breaking down into estramustine and estradiol. Its active metabolites bind microtubule-associated proteins and beta-tubulin (structural proteins of the cell's internal skeleton), interfering with microtubule function and blocking cell division. The component causes the drug to concentrate selectively in estrogen receptor-positive tissue such as prostate and breast tumor cells.
receptor fingerprint
Beta-tubulin / microtubule-associated proteinsInhibitor
receptorAgonist
Safetyrisks and cautions, not medical advice
Alestramustine was never marketed and has no dedicated human safety record. Because it is designed to break down into estramustine, a drug with well-documented estrogenic and antimitotic side effects (nausea, fluid retention, thromboembolic risk), similar concerns would be expected but are not confirmed for alestramustine itself.
Subjective profileweighing the evidence above
Nothing to evaluate and nothing anyone should take. It is an unmarketed chemotherapy prodrug with no human data at all, and its parent estramustine carries real clotting risk. This is a chemistry footnote rather than a compound with a use.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Alestramustine used for?
It was investigated only as an experimental cancer chemotherapy agent; it was never marketed and is not used for anything today.
How does Alestramustine work?
It acts as a prodrug that breaks down into estramustine and estradiol, which together bind tubulin and microtubule-associated proteins to block cancer cell division, while the estrogen component helps target estrogen receptor-positive tumors.
Is Alestramustine well-researched?
No. It has minimal published data and was never advanced through clinical development, unlike its parent compound estramustine.
Limitations of the evidence
- Never tested in humans, so no real safety data exists
Adverse effects
- Related estrogen-linked chemotherapy agents carry risks of fluid retention and blood clotting